Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
BACKGROUND
The oncogene CDC25B phosphatase plays an important role in cancer cell growth. We have recently reported that patients with esophageal squamous cell carcinoma (ESCC) have significantly higher serum levels of CDC25B autoantibodies (CDC25B-Abs) than both healthy individuals and patients with other types of cancer; however, the potential diagnostic or prognostic significance of CDC25B-Abs is not clear. The aim of this study is to evaluate the clinical significance of serum CDC25B-Abs in patients with ESCC.


METHODS
CDC25B autoantibodies were measured in sera from both 134 patients with primary ESCC and 134 healthy controls using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which anti-CDC25B antibodies bound CDC25B antigen purified from Eca-109 ESCC tumor cells. The clinicopathologic significance of CDC25B serum autoantibodies was compared to that of the tumor markers carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragment antigen 21-1(CYFRA21-1).


RESULTS
Higher levels of CDC25B autoantibodies were present in sera from patients with ESCC (A450 = 0.917, SD = 0.473) than in sera from healthy control subjects (A450 = 0.378, SD = 0.262, P < 0.001). The area under the receiver operating characteristic (ROC) curve for CDC25B-Abs was 0.870 (95% CI: 0.835-0.920). The sensitivity and specificity of CDC25B-Abs for detection of ESCC were 56.7% and 91.0%, respectively, when CDC25-Abs-positive samples were defined as those with an A450 greater than the cut-off value of 0.725. Relatively few patients tested positive for the tumor markers CEA, SCC-Ag and CYFRA21-1 (13.4%, 17.2%, and 32.1%, respectively). A significantly higher number of patients with ESCC tested positive for a combination of CEA, SCC, CYFRA21-1 and CDC25B-Abs (64.2%) than for a combination of CEA, SCC-Ag and CYFRA21-1 (41.0%, P < 0.001). The concentration of CDC25B autoantibodies in serum was significantly correlated with tumor stage (P < 0.001). Although examination of the total patient pool showed no obvious relationship between CDC25B autoantibodies and overall survival, in the subgroup of patients with stage III-IV tumors, the cumulative five-year survival rate of CDC25B-seropositive patients was 6.7%, while that of CDC25B-seronegative patients was 43.4% (P = 0.001, log-rank). In the N1 subgroup, the cumulative five-year survival rate of CDC25B-seropositive patients was 13.6%, while that of CDC25B-seronegative patients was 54.5% (P = 0.040, log-rank).


CONCLUSIONS
Detection of serum CDC25B-Abs is superior to detection of the tumor markers CEA, SCC-Ag and CYFRA21-1 for diagnosis of ESCC, and CDC25B-Abs are a potential prognostic serological marker for advanced ESCC.
Dong
Jun
J
The Second Affiliated Hospital of Guangzhou Medical University, Gyangzhou, China.
Zeng
Bo-hang
BH
Xu
Li-hua
LH
Wang
Jun-ye
JY
Li
Man-zhi
MZ
Zeng
Mu-sheng
MS
Liu
Wan-li
WL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000175:diagnosis* / Q000276:immunology* / Q000473:pathology; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D004938:Esophageal Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D053539:Keratin-19; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D012680:Sensitivity and Specificity; D015843:Serpins / Q000097:blood; D020687:cdc25 Phosphatases / Q000276:immunology*
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; D015843:Serpins; C102012:antigen CYFRA21.1; C051072:squamous cell carcinoma-related antigen; C517008:CDC25B protein, human; D020687:cdc25 Phosphatases
Br J Cancer. 2001 Aug 3;85(3):412-21
11487274
Anticancer Res. 2004 Sep-Oct;24(5B):3245-9
15510618
BMC Cancer. 2006 Dec 22;6:296
17187659
Surgery. 2003 May;133(5):486-94
12773976
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1424-35
18559558
BMC Cancer. 2008 Aug 13;8:233
18700042
Biochem Biophys Res Commun. 2008 Oct 24;375(3):440-5
18722351
Cancer Res. 2006 Jun 15;66(12):6225-32
16778197
Cancer. 1988 Dec 1;62(11):2281-6
3179942
Surgery. 2002 Jul;132(1):41-7
12110794
Cancer. 1997 May 1;79(9):1647-55
9128978
Cancer Lett. 2008 May 18;263(2):280-90
18334280
Dis Esophagus. 2007;20(2):117-22
17439594
Int J Cancer. 2000 Mar 15;85(6):791-5
10709097
Methods Mol Biol. 2008;441:175-92
18370319
Int J Oncol. 2005 Jan;26(1):77-86
15586227
Cancer Res. 2000 Jun 1;60(11):3043-50
10850455
Cancer Genet Cytogenet. 2006 Feb;165(1):25-35
16490594
Clin Cancer Res. 2000 Dec;6(12):4859-65
11156245
Cancer Lett. 2001 Nov 28;173(2):187-92
11597794
J Clin Invest. 2000 Sep;106(6):753-61
10995786
Prog Cell Cycle Res. 2000;4:107-14
10740819
Nat Protoc. 2006;1(1):452-60
17406268
Cancer. 1997 Nov 1;80(9):1803-4
9351551
Eur J Surg Oncol. 1996 Oct;22(5):505-7
8903494
Cancer Sci. 2006 May;97(5):380-6
16630135
Science. 1995 Sep 15;269(5230):1575-7
7667636
Biomarkers. 2009 Nov;14(7):480-5
19863186
EMBO J. 2002 Nov 1;21(21):5911-20
12411508
N Engl J Med. 2003 Dec 4;349(23):2241-52
14657432
Cancer Res. 1998 Apr 15;58(8):1762-7
9563496
Proteomics. 2006 May;6(10):3199-209
16596707
Int J Oncol. 2007 Jan;30(1):97-103
17143517
Chest. 1999 Dec;116(6 Suppl):463S-465S
10619509
Clin Cancer Res. 2001 Aug;7(8):2213-21
11489794
N Engl J Med. 2005 Sep 22;353(12):1288-90
16177255
Cancer Lett. 2005 Nov 18;229(2):291-7
16095809
Chem Biol. 2004 Aug;11(8):1043-51
15324805